JP2017525752A - 静注用免疫グロブリンの精製組成物及びリンパ球を調整しｂ型肝炎を治療するためのｋｈタンパク質 - Google Patents

静注用免疫グロブリンの精製組成物及びリンパ球を調整しｂ型肝炎を治療するためのｋｈタンパク質 Download PDF

Info

Publication number
JP2017525752A
JP2017525752A JP2017515008A JP2017515008A JP2017525752A JP 2017525752 A JP2017525752 A JP 2017525752A JP 2017515008 A JP2017515008 A JP 2017515008A JP 2017515008 A JP2017515008 A JP 2017515008A JP 2017525752 A JP2017525752 A JP 2017525752A
Authority
JP
Japan
Prior art keywords
amino acid
protein
substantially pure
acid seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017515008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525752A5 (enExample
Inventor
キュー ホアン
キュー ホアン
Original Assignee
レア アンチボディ アンチジェン サプライ インク
レア アンチボディ アンチジェン サプライ インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54699755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2017525752(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by レア アンチボディ アンチジェン サプライ インク, レア アンチボディ アンチジェン サプライ インク filed Critical レア アンチボディ アンチジェン サプライ インク
Publication of JP2017525752A publication Critical patent/JP2017525752A/ja
Publication of JP2017525752A5 publication Critical patent/JP2017525752A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017515008A 2014-05-28 2015-05-28 静注用免疫グロブリンの精製組成物及びリンパ球を調整しｂ型肝炎を治療するためのｋｈタンパク質 Pending JP2017525752A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462003664P 2014-05-28 2014-05-28
US62/003,664 2014-05-28
PCT/US2015/032807 WO2015184050A1 (en) 2014-05-28 2015-05-28 Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus

Publications (2)

Publication Number Publication Date
JP2017525752A true JP2017525752A (ja) 2017-09-07
JP2017525752A5 JP2017525752A5 (enExample) 2018-05-17

Family

ID=54699755

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017515008A Pending JP2017525752A (ja) 2014-05-28 2015-05-28 静注用免疫グロブリンの精製組成物及びリンパ球を調整しｂ型肝炎を治療するためのｋｈタンパク質

Country Status (10)

Country Link
EP (1) EP3148574B1 (enExample)
JP (1) JP2017525752A (enExample)
CN (1) CN107106664A (enExample)
AU (1) AU2015266997A1 (enExample)
BR (1) BR112016027818A2 (enExample)
CA (1) CA2949994A1 (enExample)
ES (1) ES2878043T3 (enExample)
MX (1) MX2016015574A (enExample)
RU (1) RU2016151761A (enExample)
WO (1) WO2015184050A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2878043T3 (es) 2014-05-28 2021-11-18 Rare Antibody Antigen Supply Inc Composiciones purificadas de proteínas IVIG y KH para la modulación de los linfocitos y el tratamiento del virus de la hepatitis B
CN107921079A (zh) * 2015-04-02 2018-04-17 K·黄 由组分iii制造静脉注射免疫球蛋白的方法
US10583179B2 (en) * 2015-04-02 2020-03-10 Kieu Hoang Method of manufacturing and purifying prothrombin complex concentrate from Fraction III for intravenous injection and a method of curing and preventing Hemophilia A with inhibitors or Hemophilia B in patients infected with HIV-1 and HIV-2
CN118903378A (zh) * 2024-03-19 2024-11-08 北京达尔文细胞生物科技有限公司 一种蛋白聚合物在治疗渐冻症中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116482A1 (en) * 2012-01-31 2013-08-08 Shanghai Raas Blood Products Co., Ltd. Process of afod and afcc and manufacturing and purification processes of proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
TWI489994B (zh) * 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CA2639003A1 (en) * 2008-08-20 2010-02-20 Canadian Blood Services Inhibition of fc.gamma.r-mediated phagocytosis with reduced immunoglobulin preparations
JP5969458B2 (ja) * 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ アルブミン誘導体及び変異体
SG185483A1 (en) * 2010-05-14 2012-12-28 Univ Colorado Regents Improved complement receptor 2 (cr2) targeting groups
ES2878043T3 (es) 2014-05-28 2021-11-18 Rare Antibody Antigen Supply Inc Composiciones purificadas de proteínas IVIG y KH para la modulación de los linfocitos y el tratamiento del virus de la hepatitis B

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116482A1 (en) * 2012-01-31 2013-08-08 Shanghai Raas Blood Products Co., Ltd. Process of afod and afcc and manufacturing and purification processes of proteins

Also Published As

Publication number Publication date
ES2878043T3 (es) 2021-11-18
RU2016151761A3 (enExample) 2018-12-26
WO2015184050A1 (en) 2015-12-03
CA2949994A1 (en) 2015-12-03
EP3148574B1 (en) 2021-04-14
CN107106664A (zh) 2017-08-29
EP3148574A4 (en) 2017-04-05
BR112016027818A2 (pt) 2017-10-24
EP3148574A1 (en) 2017-04-05
RU2016151761A (ru) 2018-07-03
MX2016015574A (es) 2018-05-28
AU2015266997A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
Kink et al. Macrophages educated with exosomes from primed mesenchymal stem cells treat acute radiation syndrome by promoting hematopoietic recovery
JP6803339B2 (ja) 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
US12472182B2 (en) Compositions comprising regulatory t cells and methods of making and using the same
CA2946511C (en) Compositions and methods for treating cytokine-related disorders
US20230066340A1 (en) Populations of enriched regulatory t cells and methods for producing same
JP2017525752A (ja) 静注用免疫グロブリンの精製組成物及びリンパ球を調整しｂ型肝炎を治療するためのｋｈタンパク質
WO2017079881A1 (zh) 增强对异常细胞杀伤力的方法和药物组合物
JP2024510649A (ja) 制御性ｔ細胞を含む組成物及びそれを使用する方法
CN109232740B (zh) 一种抗pd-l1抗体及其在抗肿瘤治疗中的应用
CN1660427A (zh) 体外光除去法与抗－tnf治疗的组合
JP3147916B2 (ja) 体外免疫方法
CN110540960A (zh) 结合有免疫检查点阻断剂的t淋巴细胞及其在制备抗肿瘤药物中的应用
US20180021376A1 (en) Naming of KH1 through KH55 good healthy cells synthesizes the KH1 through KH55 proteins
JP3970916B2 (ja) ナチュラルキラー細胞の増殖剤及び増殖方法
CN118047874B (zh) 一种双特异性抗体及其与t细胞在制备治疗肿瘤药物中的应用
US20220087233A1 (en) Non-human animal models of sézary syndrome
WO2025235766A1 (en) Compositions and methods of using extracellular vesicles
JP5084012B2 (ja) イディオタイプ抗原用担体およびそれを用いたイディオタイプワクチン
WO2025064883A2 (en) Engineered chimeric fusion protein compositions and methods of use thereof
CN103880957A (zh) 抗cd20抗原的抗体l1h1及其应用
CN103936855A (zh) 抗cd20抗原的抗体l4h5及其应用
CN111568927A (zh) 一种msc用于调节记忆b细胞数量的应用
Hullmann et al. Critical role of epidermal growth factor receptor in neutropenic fever
CN106220725A (zh) 一种液泡膜蛋白1免疫原多肽及其用途
AU2015213389A1 (en) Human facilitating cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190326

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191029